Commercialisation

The Centenary Institute of Cancer Medicine and Cell Biology is one of Australia's leading medical research institutes. The Centenary Institute actively capitalises on its innovative research by protecting intellectual property that has commercial potential. Commercialisation of our research is one way we aim to achieve our mission of better health through excellence in medical research and its translation.

To protect the rights of Centenary Institute and its staff, the organisation uses a material transfer agreement (MTA) to confirm the terms and conditions for the transfer of materials to academic researchers. The MTA is based on an Association of University Technology Managers agreement. In the first instance researchers should contact the Centenary Institute researcher from whom the materials are desired.

In 2006, the Centenary Institute became a member of Bio-Link. Bio-Link is a life sciences commercialisation company, which facilitates partnerships based on technology review, project management, business development and deal negotiation. They are currently commercialising a genetic biomarker that predicts drug response in cancer patients treated with proteasome inhibitors such as Velcade. More information on this project is available on the Bio-Link site.

In 2007, the Centenary Institute became a member of the Medical Research Commercialisation Fund. The Fund invests in early stage research that has commercial potential. A number of medical research institutes are members of the Fund. The fund is supported by the NSW and Victorian State Governments.

For more information on partnerships, licensing opportunities and technology transfer contact Chief Operating Officer, Dr Nick Pearce on +61 2 9565 6190 or email .